CombiMatrix and the CBRC of Japan Enter Into a Technology Access and Purchase Agreement.Business Editors & Health/Medical Writers BIOWIRE2K NEWPORT BEACH Newport Beach, residential and resort city (1990 pop. 66,643), Orange co., S Calif., on Newport Bay and the Pacific Ocean; inc. 1906. It is a popular seaside resort and yachting center. Manufactures include electrical and medical equipment, computers, boats, and adhesives. , Calif.--(BW HealthWire)--April 26, 2002 Acacia Research Corporation (Nasdaq:ACRI) announced today that its subsidiary CombiMatrix Corporation's Japanese subsidiary, has entered into a technology access and purchase agreement in Japan with the Computational Biology Research Center, a division of the Japanese National Institute of Advanced Industrial Science and Technology The National Institute of Advanced Industrial Science and Technology (産業技術総合研究所 . The CBRC CBRC China Banking Regulatory Commission CBRC Cutaneous Biology Research Center CBRC Canadian Business Resource Centre CBRC Copenhagen Brain Research Center CBRC Colorado Business Resource Center CBRC Combat Brigade Refresher Course has purchased and installed a CombiMatrix gene chip synthesizer synthesizer Machine that electronically generates and modifies sounds, frequently with the use of a digital computer, for use in the composition of electronic music and in live performance. and entered into a multi-year agreement to purchase blank chips that will be used to synthesize custom gene chips. The agreement also gives CBRC access to the CombiMatrix set of informatics tools to help in their efforts to expand biotechnology related businesses in Japan. Dr. Yutaka Akiyama, Director of the CBRC said, "We investigated several technologies currently on the market and found that the CombiMatrix system best suited our needs from the flexibility, customization and cost standpoint. The CombiMatrix technology will help us to quickly verify many of our predictions and to make fast changes to our programs as well as quickly reiterate experimental design." "We are delighted that the CBRC has chosen the CombiMatrix Custom Microarray Synthesizer for their microarray research," said Michael Chansler, Director of International Business Development at CombiMatrix. "Dr. Akiyama is a recognized leader in bioinformatics theory, process and design and has assembled an impressive group of researchers at the CBRC. The CBRC collaborates on several projects with public and private companies in the biotech and pharmaceutical industries in Japan. His team and partners will be able to take full advantage of the benefits our microarray technology offers to the drug discovery market." The CombiMatrix Custom Microarray Synthesizer allows pharmaceutical and life science researchers to specify gene targets, design and synthesize custom semiconductor based microarrays. All equipment, software and database technologies can be installed behind the firewall of the customer for privacy of data and speed of experimental design reiteration. CombiMatrix KK, a joint venture between CombiMatrix Corporation and Marubeni Corporation, is the subsidiary and exclusive supplier of CombiMatrix products in Japan. The CBRC is a center for excellence for the design and implementation of advanced information science technology and large-scale high-speed computational systems for use in biotechnology. About CombiMatrix CombiMatrix is developing a platform technology that has a wide range of applications, from DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics to immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. The platform allows the company to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The company is designing its products principally to be responsive to the needs of pharmaceutical, biotechnology, and academic researchers in analyzing raw genomic data in the discovery and development of pharmaceutical products. CombiMatrix's Web site is located at www.combimatrix.com. About Acacia Research Corporation Acacia Research develops, licenses and provides products for the life science and media technology sectors. Acacia licenses its V-chip technology to television manufacturers and owns pioneering technology for digital streaming and video-on-demand. Acacia's CombiMatrix subsidiary is developing a biochip biochip Small-scale device, analogous to an integrated circuit, constructed of or used to analyze organic molecules associated with living organisms. One type of theoretical biochip is a small device constructed of large organic molecules, such as proteins, and capable of technology for the life science market. Acacia Research's website is located at www.acaciaresearch.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. , recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion